Author

A. Ferro

Institutions: Ospedale Santa Chiara, Provincia Autonoma di Trento

Observed institutions: Ospedale Santa Chiara, Provincia Autonoma di Trento

ORCID: 0000-0003-4109-6769

Observed ORCID: 0000-0003-4109-6769

OpenAlex ID: A5126265403

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study

2026 · M.E. Cazzaniga, V. Cogliati, et al. · ESMO Real World Data and Digital Oncology · 2

Abstract PS2-08-11: Artificial Intelligence (AI)-based spatial assessment of tumor-infiltrating lymphocytes (TIL) and outcome in early HER2+ breast cancer (BC): ancillary study of the phase III adjuvant ShortHER trial

2026 · M. Dieci, K. AbdulJabbar, et al. · Clinical Cancer Research · 1

Abstract PS5-04-08: Abemaciclib plus endocrine therapy in HR+/HER2- advanced breast cancer: insights from an Italian retrospective observational study

2026 · E. Munzone, V. Guarneri, et al. · Clinical Cancer Research

Works count: 3

Citation count: 3

H-index: 1

I10-index: